Infectious disease
The interim analysis was of a two-dose vaccination schedule given 28 days apart at three different dose levels, 25, 100 and 250 micrograms in 45 healthy adults ranging in age from 18 to 55 years.
Ken Frazier, Merck’s chief executive officer, is reminding the world that vaccine development takes time, typically a decade, and hoping for a viable vaccine against the novel coronavirus by the end of December is premature.
It has already administered the first doses of the candidate in healthy human subjects, and the company intends to initiate a Phase II/III trial this coming October.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 15, 2020.
An unnamed U.S. official told the news agency that vaccine manufacturing under development in conjunction with the federal government’s Operation Warp Speed program is likely to begin within the next four to six weeks.
Thomas Olin, chief executive officer of Kancera, took time to discuss the company, the Fracktalkine pathway and the upcoming clinical trial.
In general, studies have shown that people with Type O blood appear to be more protected than those with Type A, who are seemingly more vulnerable, according to NBC News.
Itolizumab is a first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 13, 2020.
The designation will provide for an expedited pathway for regulatory review of the preventative medication, which could come later this year.
PRESS RELEASES